Tokyo-based AGC Inc. has completed the acquisition of Spain’s synthetic pharmaceutical active ingredient manufacturer, Malgrat Pharma Chemicals (MPC).   With the addition of MPC, it has now become possible for AGC to manufacture and process intermediates for synthetic pharmaceuticals in Europe all the way through active ingredients. AGC had been serving pharmaceutical customers with its original fluorine technology and experience in in-house drug discovery from Japan, and this will be an a...